Core Viewpoint - Fosun Pharma (02196.HK) announced the board's resolution to plan for the spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. on the Hong Kong Stock Exchange by October 28, 2025 [1] Group 1: Company Overview - Fosun Antigen was established in July 2012 and is primarily focused on the research, production, and sales of human vaccines [1] - As of the announcement date, Shanghai Fosun Pharma Industrial Development Co., Ltd. holds a 70.08% stake in Fosun Antigen, while 17 other shareholders own the remaining 29.92% [1] Group 2: Product Development - Fosun Antigen has developed a technical platform for both bacterial and viral vaccines [1] - The company has received approval for several self-developed human vaccines in mainland China, including rabies vaccines (Vero cell), lyophilized rabies vaccines (Vero cell), trivalent influenza virus split vaccine, and quadrivalent influenza virus split vaccine [1] - The 13-valent pneumococcal conjugate vaccine is currently in Phase III clinical trials, while the lyophilized rabies vaccine (human diploid cells) and 24-valent pneumococcal polysaccharide conjugate vaccine are in Phase I clinical trials [1] - The 23-valent pneumococcal polysaccharide vaccine has received approval for clinical trials [1]

Core Viewpoint - The company has announced plans for a spin-off listing of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., on the Hong Kong Stock Exchange, indicating a strategic move to enhance its focus on vaccine development and commercialization [1] Group 1 - The board of directors approved the proposal for the spin-off listing on October 28, 2025 [1] - Fosun Antigen was established in July 2012 and specializes in the research, production, and sales of human vaccines [1] - The company has developed technical platforms for both bacterial and viral vaccines [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 本公司股東及潛在投資者務請注意，建議分拆上市尚處於初步籌劃階段。本公司將遵守香 港聯合交易所有限公司證券上市規則（「上市規則」），並根據上市規則適時就建議分拆上市 進一步發佈相關公告。本公司概不保證建議分拆上市將會於何時、以何價格進行或完成。 因此，本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 自願公告 建議籌劃復星安特金於聯交所分拆上市 本公告乃由上海復星醫藥（ 集團）股份有限公司（「本公司」）自願作出。 2025年10月28日，本公司董事會（「董事會」）決議批准建議籌劃本公司附屬公司復星安特金 （ 成都 ）生物製藥有限公司（「復星安特金」）於香港聯合交易所有限公司（「聯交所」）的分拆上 市（「建議分拆上市」）。 復星安特金成立於2012年7月。截至本公告日期，本公 ...

Investment Overview - Fosun Pharma (600196) announced that its subsidiary, Fosun Pharma Industry, plans to invest 100 million RMB as a limited partner (LP) in a private equity investment fund, which aims to raise a total of 1 billion RMB. The fund will primarily invest in areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicinal supplements, and synthetic biology [1] Fund Structure - The investment structure includes Fosun Pharma Industry committing 10% of the fund, while Chengdu Zhongchan Phase II Fund and Chengdu High-tech Source Fund each contribute 19.7%. Chengdu Jiaozi Industry Fund contributes 14.85%, and Huaren Fang Investment collectively contributes 21.75%, with the remainder coming from other investors [1] Fund Management - The fund will be managed by China Resources Capital, with a duration of 7 years, which includes a 3-year investment period and a 4-year exit period. There is an option to extend the duration by 1 year [2] Decision-Making Mechanism - The investment committee consists of 7 members, with Fosun Pharma Industry having the right to nominate 1 member. Major decisions require the approval of more than 2/3 of the committee members [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 持續關連交易年度上限之修訂 持續關連交易年度上限之修訂 兹提述該公告，內容有關（ 其中包括 ）就本集團與復星國際及╱或其聯繫人互相提供產品 和服務訂立復星國際互供框架協議。該協議自2025年1月1日起至2025年12月31日止，為 期一年。 為滿足本集團於2025年最後一個季度的進一步業務開展需要，預期會使復星國際互供框 架協議範圍內的復星國際及╱或其聯繫人向本集團提供服務出現增量，而原預計的復星 國際及╱或其聯繫人向本集團提供服務的年度上限將不足以滿足截至2025年12月31日止 年度復星國際互供框架協議項下可能進行的相關交易之額度。因此，董事會建議復星國 際及╱或其聯繫人於 ...

格隆汇10月28日丨复星医药(600196.SH)发布2025年第三季度报告，第三季度营收为98.79亿元，同比下 降5.46%；净利润为8.21亿元，同比增长4.52%。前三季度净利润为25.23亿元，同比增长25.5%。本期营 收下降主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳 健增长。 ...

2025年前三季度利润总额及归属于上市公司股东的净利润、基本及稀释每股收益同比增加，主要系出售 和睦家剩余权益以及其他非核心资产的收益贡献。 2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品 集中带量采购开展的影响，但同期创新药品收入稳健增长。 智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿 元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。 ...

Core Viewpoint - Fosun Pharma plans to spin off its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange to enhance corporate governance and sustainable development, aiming to maximize shareholder value [1] Group 1: Spin-off Details - The proposed spin-off is expected to broaden financing channels and enhance market competitiveness for Fosun Antigen [1] - The spin-off will not affect the company's control over Fosun Antigen or its other business operations and profitability [1] - Fosun Antigen was established in July 2012 with a registered capital of approximately 83.13 million yuan, and Fosun Pharma holds about 70.08% of its shares [1] Group 2: Product Development - Fosun Antigen focuses on the research, production, and sales of human vaccines, having established technical platforms for bacterial and viral vaccines [2] - The company has developed several vaccines that have been approved for sale in China, including rabies vaccines and various influenza vaccines [2] - Additionally, a 13-valent pneumococcal conjugate vaccine is in Phase III clinical trials, while other vaccines are in earlier clinical trial phases [2]

北京商报讯（记者 丁宁）10月28日晚间，复星医药（600196）发布2025年三季报显示，公司前三季度 实现营业收入293.93亿元，同比下降4.91%；归属净利润25.23亿元，同比增长25.5%。 复星医药表示，公司前三季度营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带 量采购开展的影响，但同期创新药品收入稳健增长。公司前三季度归属净利润同比增加，主要系出售和 睦家剩余权益以及其他非核心资产的收益贡献。 ...

格隆汇10月28日丨复星医药(02196.HK)发布公告，2025年前三季度，实现营业收入293.93亿元(人民币， 下同)，同比减少4.91%；归属于上市公司股东的净利润25.23亿元，同比增加25.50%；归属于上市公司 股东的扣除非经常性损益的净利润15.73亿元，同比减少14.32%；基本每股收益0.95元。 ...